A Study of a Side Effects and Resource Navigation Program for People With Cancer

Study summary

The purpose of this study is to find out if the navigation program helps participants manage immunotherapy treatment better than usual care. Investigators will also look at how the navigation program impacts participants' quality of life. Investigators will measure quality of life by having participants complete questionnaires.

Ask AI to explain this study

Start here

Key things to know

Main goalDiagnostic

This describes the study’s primary purpose.

What is being studiedImmunotherapy CARE Program

The study team can explain what participation involves.

Who it may be forKidney Cancer · Bladder Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 20, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Interventional

Where is it offered?8 U.S. locations

Locations may change over time.

Who runs it?Memorial Sloan Kettering Cancer Center

Study sponsor

Study overview

What this study is about

Purpose: Diagnostic
Study type: Interventional
Phase: Not applicable
Sponsor: Memorial Sloan Kettering Cancer Center
Interventions being studied: Other: Immunotherapy CARE Program

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Immunotherapy→

Study topics

Survivorship and quality of life→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Documentation of Disease o Patient must have pathologically confirmed kidney, bladder, breast, or lung cancer (per EMR)
Prior Treatment o Within three weeks (+/- 3 weeks) of starting PD-1 or PD(L)-1 immune checkpoint inhibitors as monotherapy or in combination with other therapies (per EMR)
Age ≥ 18 (per EMR)
Not Pregnant and Not Nursing (per self-report)
At least one essential need (e.g., food, transportation, housing), as determined by the ICCAN Essential Needs Screener (per self-report)
Lives in New York metro area, including Long Island, New Jersey, Connecticut, and Pennsylvania (per self-report)
Can speak English or Spanish (per self-report)
Has no significant psychiatric disturbance sufficient to preclude completion of the assessment measures, interview, or informed consent (i.e., acute psychiatric symptoms which require individual treatment) (per EMR, patient's care team, or study team)
Has no presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per EMR, patient's care team, or study team)

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)Basking Ridge, New Jersey
Memorial Sloan Kettering Monmouth (All Protocol Activities)Middletown, New Jersey
Memorial Sloan Kettering Bergen (All Protocol Activities)Montvale, New Jersey
Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities)Commack, New York
Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, New York
City College of New York (Data Collection AND Specimen Analysis)New York, New York
Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, New York
Memorial Sloan Kettering Nassau (All protocol activities)Rockville Centre, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 20, 2026. Always confirm current availability with the study team.

View original record ↗